A New Targeted Therapy for Triple-Negative Breast Cancer
Dual-payload antibody-drug conjugate for chemo-immunotherapy of triple-negative breast cancers
['FUNDING_R01'] · OHIO STATE UNIVERSITY · NIH-11117176
This project is developing a new targeted medicine to help patients with aggressive triple-negative breast cancer who haven't responded well to other treatments.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OHIO STATE UNIVERSITY (nih funded) |
| Locations | 1 site (Columbus, UNITED STATES) |
| Trial ID | NIH-11117176 on ClinicalTrials.gov |
What this research studies
Triple-negative breast cancers are very aggressive and often return after standard chemotherapy, with many patients not responding to current immunotherapies. This project is creating a special antibody-drug combination designed to target a protein called CD276, which is commonly found in triple-negative breast cancer cells. The new medicine aims to both directly kill cancer cells and strengthen the body's immune system to fight the tumor. Early findings in animal models suggest this approach can significantly reduce tumor growth and spread.
Who could benefit from this research
Good fit: This research is focused on developing treatments for patients with triple-negative breast cancer, particularly those whose cancer is aggressive or has not responded to standard chemotherapy or immunotherapy.
Not a fit: Patients without triple-negative breast cancer or those whose tumors do not express the CD276 protein may not benefit from this specific treatment approach.
Why it matters
Potential benefit: If successful, this new treatment could offer a more effective option for patients with triple-negative breast cancer, especially those who have not responded to existing therapies.
How similar studies have performed: While combined and targeted therapies have shown promise in treating metastatic triple-negative breast cancer, this specific dual-payload antibody-drug conjugate targeting CD276 represents a novel approach.
Where this research is happening
Columbus, UNITED STATES
- OHIO STATE UNIVERSITY — Columbus, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LIU, XIAOGUANG MARGARET — OHIO STATE UNIVERSITY
- Study coordinator: LIU, XIAOGUANG MARGARET
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.